Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

Drucker, 2006, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, Lancet, 368, 1605, 10.1016/S0140-6736(06)69705-5 Garber, 2011, Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability, Diabetes Care, 34, S279, 10.2337/dc11-s231 Matthews, 2008, Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes, J Clin Endocrinol Metab, 93, 4810, 10.1210/jc.2008-1518 Rosenstock, 2009, Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing, Diabetes Care, 32, 1880, 10.2337/dc09-0366 Rosenstock, 2010, Albiglutide, Drugs Fut, 35, 701, 10.1358/dof.2010.035.09.1516042 Bush, 2009, Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects, Diabetes Obes Metab, 11, 498, 10.1111/j.1463-1326.2008.00992.x Brod, 2006, Measuring the impact of diabetes through patient report of treatment satisfaction, productivity and symptom experience, Qual Life Res, 15, 481, 10.1007/s11136-005-1624-6 Blevins, 2011, DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes, J Clin Endocrinol Metab, 96, 1301, 10.1210/jc.2010-2081 Drucker, 2008, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study, Lancet, 372, 1240, 10.1016/S0140-6736(08)61206-4 Buse, 2013, Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study, Lancet, 381, 117, 10.1016/S0140-6736(12)61267-7 Buse, 2009, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6), Lancet, 374, 39, 10.1016/S0140-6736(09)60659-0 Garber, 2009, Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial, Lancet, 373, 473, 10.1016/S0140-6736(08)61246-5 Marre, 2009, Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU), Diabet Med, 26, 268, 10.1111/j.1464-5491.2009.02666.x Nauck, 2009, Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study, Diabetes Care, 32, 84, 10.2337/dc08-1355 Russell-Jones, 2009, Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial, Diabetologia, 52, 2046, 10.1007/s00125-009-1472-y Zinman, 2009, Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD), Diabetes Care, 32, 1224, 10.2337/dc08-2124 Pratley, 2011, One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial, Int J Clin Pract, 65, 397, 10.1111/j.1742-1241.2011.02656.x Mundil, 2012, GLP-1 receptor agonists: a clinical perspective on cardiovascular effects, Diab Vasc Dis Res, 9, 95, 10.1177/1479164112441526 Malloy, 2012, Increased variability and abnormalities in pancreatic enzyme concentrations in otherwise asymptomatic subjects with type 2 diabetes, Diabetes Metab Syndr Obes, 5, 419 Hayes, 2012, Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects, Physiol Behav, 106, 413, 10.1016/j.physbeh.2012.02.017 Cabou, 2008, Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity, Diabetes, 57, 2577, 10.2337/db08-0121 Inzucchi, 2012, Management of hyperglycaemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia, 55, 1577, 10.1007/s00125-012-2534-0